Your browser doesn't support javascript.
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.
Jyssum, Ingrid; Kared, Hassen; Tran, Trung T; Tveter, Anne T; Provan, Sella A; Sexton, Joseph; Jørgensen, Kristin K; Jahnsen, Jørgen; Kro, Grete B; Warren, David J; Vaage, Eline B; Kvien, Tore K; Nissen-Meyer, Lise-Sofie H; Anderson, Ane Marie; Grødeland, Gunnveig; Haavardsholm, Espen A; Vaage, John Torgils; Mjaaland, Siri; Syversen, Silje Watterdal; Lund-Johansen, Fridtjof; Munthe, Ludvig A; Goll, Guro Løvik.
  • Jyssum I; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Kared H; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Tran TT; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Tveter AT; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Provan SA; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Sexton J; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Jørgensen KK; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Jahnsen J; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Kro GB; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
  • Warren DJ; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Vaage EB; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
  • Kvien TK; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Nissen-Meyer LH; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
  • Anderson AM; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Grødeland G; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Haavardsholm EA; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Vaage JT; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Mjaaland S; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Syversen SW; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Lund-Johansen F; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Munthe LA; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Goll GL; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
Lancet Rheumatol ; 4(3): e177-e187, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1605659
ABSTRACT

BACKGROUND:

In rituximab-treated patients with rheumatoid arthritis, humoral and cellular immune responses after two or three doses of SARS-CoV-2 vaccines are not well characterised. We aimed to address this knowledge gap.

METHODS:

This prospective, cohort study (Nor-vaC) was done at two hospitals in Norway. For this sub-study, we enrolled patients with rheumatoid arthritis on rituximab treatment and healthy controls who received SARS-CoV-2 vaccines according to the Norwegian national vaccination programme. Patients with insufficient serological responses to two doses (antibody to the receptor-binding domain [RBD] of the SARS-CoV-2 spike protein concentration <100 arbitrary units [AU]/mL) were allotted a third vaccine dose. Antibodies to the RBD of the SARS-CoV-2 spike protein were measured in serum 2-4 weeks after the second and third doses. Vaccine-elicited T-cell responses were assessed in vitro using blood samples taken before and 7-10 days after the second dose and 3 weeks after the third dose from a subset of patients by stimulating cryopreserved peripheral blood mononuclear cells with spike protein peptides. The main outcomes were the proportions of participants with serological responses (anti-RBD antibody concentrations of ≥70 AU/mL) and T-cell responses to spike peptides following two and three doses of SARS-CoV-2 vaccines. The study is registered at ClinicalTrials.gov, NCT04798625, and is ongoing.

FINDINGS:

Between Feb 9, 2021, and May 27, 2021, 90 patients were enrolled, 87 of whom donated serum and were included in our analyses (69 [79·3%] women and 18 [20·7%] men). 1114 healthy controls were included (854 [76·7%] women and 260 [23·3%] men). 49 patients were allotted a third vaccine dose. 19 (21·8%) of 87 patients, compared with 1096 (98·4%) of 1114 healthy controls, had a serological response after two doses (p<0·0001). Time since last rituximab infusion (median 267 days [IQR 222-324] in responders vs 107 days [80-152] in non-responders) and vaccine type (mRNA-1273 vs BNT162b2) were significantly associated with serological response (adjusting for age and sex). After two doses, 10 (53%) of 19 patients had CD4+ T-cell responses and 14 (74%) had CD8+ T-cell responses. A third vaccine dose induced serological responses in eight (16·3%) of 49 patients, but induced CD4+ and CD8+ T-cell responses in all patients assessed (n=12), including responses to the SARS-CoV-2 delta variant (B.1.617.2). Adverse events were reported in 32 (48%) of 67 patients and in 191 (78%) of 244 healthy controls after two doses, with the frequency not increasing after the third dose. There were no serious adverse events or deaths.

INTERPRETATION:

This study provides important insight into the divergent humoral and cellular responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis. A third vaccine dose given 6-9 months after a rituximab infusion might not induce a serological response, but could be considered to boost the cellular immune response.

FUNDING:

The Coalition for Epidemic Preparedness Innovations, Research Council of Norway Covid, the KG Jebsen Foundation, Oslo University Hospital, the University of Oslo, the South-Eastern Norway Regional Health Authority, Dr Trygve Gythfeldt og frues forskningsfond, the Karin Fossum Foundation, and the Research Foundation at Diakonhjemmet Hospital.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Journal: Lancet Rheumatol Year: 2022 Document Type: Article Affiliation country: S2665-9913(21)00394-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Journal: Lancet Rheumatol Year: 2022 Document Type: Article Affiliation country: S2665-9913(21)00394-5